Literature DB >> 15662774

Low-grade gliomas treated by fractionated gamma knife surgery.

Gabriela Simonová1, Josef Novotny, Roman Liscák.   

Abstract

OBJECT: The authors sought to evaluate local tumor control, complications, and progression-free survival in patients harboring low-grade gliomas who were treated with Leksell gamma knife surgery (GKS).
METHODS: During a 6-year period 70 patients were treated for verified low-grade gliomas (Grade I or II) by GKS. Statistical analysis was based on 68 patients; two patients were lost to follow up. The median patient age was 17 years. The median target volume was 4200 mm.3 The median prescription dose was 25 Gy. The median number of fractions was five. Ninety-five percent of patients were treated in five daily fractions. Partial or complete tumor regression was achieved in 83% of patients with a median time to response of 18 months. There was moderate acute or late toxicity in not more than 5% of patients. In this series the progression-free survival was 92% at 3 years and 88% at 5 years.
CONCLUSIONS: Relatively high local tumor control with minimal complications was achieved.

Entities:  

Mesh:

Year:  2005        PMID: 15662774     DOI: 10.3171/jns.2005.102.s_supplement.0019

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  3 in total

Review 1.  The role of radiotherapy in the management of patients with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.

Authors:  Timothy C Ryken; Ian Parney; John Buatti; Steven N Kalkanis; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2015-11-03       Impact factor: 4.130

2.  Stereotaxic gamma knife surgery in treatment of critically located pilocytic astrocytoma: preliminary result.

Authors:  Raef F A Hafez
Journal:  World J Surg Oncol       Date:  2007-03-29       Impact factor: 2.754

Review 3.  Management of Gliomas: Overview of the Latest Technological Advancements and Related Behavioral Drawbacks.

Authors:  L Ganau; M Paris; G K Ligarotti; M Ganau
Journal:  Behav Neurol       Date:  2015-08-09       Impact factor: 3.342

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.